

PRESS RELEASE



Ceva Animal Health inaugurates Biogenovac, a state-of-the-art Genomics Laboratory to Create Tomorrow's Vaccines and Prevent Future Health Crises

Libourne, February 6, 2025 — [Ceva Animal Health](#) (Ceva), the world's fifth-largest animal health company, inaugurates Biogenovac, its brand-new genomics research laboratory, in Beaucouzé (Maine-et-Loire), France. The laboratory, which is partly financed by the French government as part of its recovery plan and the Pays de la Loire region, reinforces Ceva's commitment to preventing future health crises by anticipating variations in viral strains and combating emerging animal diseases.

Innovative technologies to design and produce the vaccines of the future to combat emerging diseases.

Responding to the challenges posed by the rise of new epizootics, this new technological platform will enable Ceva to develop effective, industrialized, and competitive vaccine solutions capable of rapidly responding to the rise of emerging infectious diseases.

With this investment, Ceva confirms its leadership in animal health research and innovation and its commitment to the One Health concept.

This new platform is equipped with cutting-edge technological innovations incorporating the latest high-throughput sequencing and bioinformatics techniques for developing nucleotide vaccines:


CEVA ANIMAL HEALTH

PRESS CONTACT

Emilie Barrail

emilie.barrail@ceva.com

Tél : +33 7 85 61 81 15



The site boasts a centralized bioinformatics interface facilitating the detailed analysis and processing of a large volume of vaccine data (coverage, efficacy, antigen design, etc.). This will enable vaccines to be adapted as closely as possible to the realities of the field, thereby enhancing their effectiveness.

Present in 47 countries with 21 R&D centres across the globe, Ceva is deeply attached to global health and industrial sovereignty and plays an active role in it investing 10% of its turnover annually into R&D endeavours. This initiative is a unique opportunity to develop effective, safe and scientifically innovative responses to the major diseases affecting our livestock.

Commenting on the inauguration, **Marc Prikazsky, Chairman and CEO of Ceva Animal Health**, said: *"The inauguration of Biogenovac is a decisive step for Ceva and our ability to continue innovating for the future of animal vaccination. This project testifies to our determination to support breeders by developing tailor-made solutions to emerging diseases. This investment also embodies our commitment to the dynamism of our regions and to our health and industrial sovereignty."*

-- END --

About Ceva Animal Health



Ceva Animal Health (Ceva) is the 5th global animal health company, led by experienced veterinarians, whose mission is to provide innovative health solutions for all animals to ensure the highest level of care and well-being. Our portfolio includes preventive medicine such as vaccines and animal welfare products, pharmaceutical solutions for farm and companion animals, as well as equipment and services to provide the best experience for our customers.

With more than 7,000 employees located in 47 countries, Ceva strives daily to bring to life its vision as a One Health company: "Together, beyond animal health".

2023 turnover: €1.7 billion.

FOR MORE
INFORMATION

www.ceva.com

